Stocks

Despite being a disappointing performer, I remain a big fan of Budweiser and Stella Artois owner AB InBev (BUD). I know that may sound daft given its ongoing struggle to digest the $110b purchase of SABMiller a few years ago, and that’s before even mentioning the woeful stock returns in…

As regular readers will know, Molson Coors (TAP) had its issues even before COVID hit. In very broad terms I think you can boil those down to two points. Firstly, the company took on a bunch of debt to buy out the rest of the MillerCoors JV in 2016. Debt…

A year ago it might have been tough to imagine Toronto Dominion (TD) putting down the kind of financial results it has of late. The economic environment was obviously pretty darn scary back then, with the early economic data resembling nothing ever seen before. The potentially devastating impact to bank…

Although it comes under a single ticker, Johnson & Johnson (JNJ) is more akin to a giant one-stop healthcare shop. Folks likely know the consumer division thanks to brands like Listerine, Neutrogena and Tylenol. Its pharmaceutical segment sells patented drugs across a range of areas – oncology, immunology, neurology, infectious…

A year ago it would have been difficult to imagine a restaurant stock having a solid 2020. Yet judging by results released early last month, Chipotle (CMG) appears to have managed just that. The Mexican-themed chain posted annual sales of around $6b last year, a 7% rise on 2019 levels.…